Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $21.4352W HIGH $50.79
Volume
401.93 K
Value Traded
25.92 M
Short % Float
16.82%
Days to Cover
7.2
+3.66%Week
+9.07%1 Month
-32.75%3 Month
-30.65%6 Month
+38.44%5 Year
+183.92%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
774.82 M
EPS (TTM)
1.47
P/E Ratio
16.17
Ent. Value
884.09 M
Total Shares
32.55 M
Float Shares
31.95 M
Insiders
1.85%
Institutions
126.68%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
COLL Catalyst Timeline
Dated clinical, regulatory and corporate events for Collegium Pharmaceutical, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Collegium Pharmaceutical, Inc.
440Total events
5Upcoming
68Tier-1 (high impact)
2015 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Exclusivity GrantedNucyntaApprovedIP / Competition
Nucynta regulatory exclusivity extended through July 2026
◆Management ChangeCorporate
Michael Donovan nominated to Board of Directors; Dr. John Fallon to retire
▲AcquisitionAZSTARYSCorporate
Collegium completes acquisition of AZSTARYS from Corium Therapeutics
Attention Deficit Hyperactivity Disorder (ADHD)source ↗
▲Quarterly UpdateCorporate
Collegium raises 2026 financial guidance to include AZSTARYS impact
◆Oral PresentationPresentation
Participation in Bank of America Securities 2026 Health Care Conference
◆Oral PresentationPresentation
25th Annual Needham Virtual Healthcare Conference Fireside Chat
◆Oral PresentationPresentation
Barclays 28th Annual Global Healthcare Conference Fireside Chat
◆Poster PresentationBelbucaApprovedPresentation
Poster presentations at PainConnect 2026 (AAPM Annual Meeting)
painsource ↗
●Poster PresentationPresentation
Two posters presented at PainConnect 2026 showcasing real-world data from pain portfolio
painsource ↗
◆Quarterly UpdateCorporate
Q4 and full-year 2025 financial results release and conference call
▲Product LaunchNucyntaApprovedPost-Market
Launch of authorized generic versions of Nucynta and Nucynta ER
painsource ↗
●Timing GuidancePresentation
Reaffirmed full-year 2026 guidance for product revenues, Jornay PM revenue, and adjusted EBITDA
▲Timing GuidancePresentation
Collegium became Official Partner of Boston Legacy Football Club
ADHDsource ↗
▲Partnership / LicenseCorporate
Collegium became an Official Partner of Boston Legacy Football Club
◆Poster PresentationPresentation
Four real-world data posters on Jornay PM at APSARD 2026
attention deficit hyperactivity disorder (ADHD)source ↗
●Poster PresentationPresentation
Four posters presented at APSARD Annual Conference highlighting real-world JORNAY PM data
ADHDsource ↗
▲Partnership / LicenseNucyntaApprovedCorporate
Supply and quality agreements with Hikma for authorized generics of Nucynta and Nucynta ER
painsource ↗
◆Exclusivity GrantedIP / Competition
Potential pediatric extension of exclusivity for Nucynta ER to December 2025
●Poster PresentationPresentation
Poster presentation at NEI Fall Congress: JORNAY PM in Practice: Real-World Evidence Exploration of Utilization and Patient Response
ADHDsource ↗
●Poster PresentationPresentation
Poster presentation at AACAP: Determining the Optimal Dose of Methylphenidate HCI (JORNAY PM) in Adolescents and Adults in a Real-World Psychiatric Setting
ADHDsource ↗
▲Quarterly UpdateCorporate
Record quarterly Jornay PM net revenue of $41.8M; prescriptions grew 20% YoY
ADHDsource ↗
Past FDA Catalysts and PDUFA Decisions
How COLL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-06-14 | Nucynta (tapentadol hydrochloride) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
17
Drugs Scored
rNPV / MCap
Top Drug
Top 72%
Micro Cap(rank 473 of 657)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Belbuca | |||
| Xtampza ER | |||
| Jornay PM | |||
| Nucynta IR | |||
| Nucynta ER | |||
| Symproic | |||
| Azstarys | |||
| Nucynta ER AG | |||
| Nucynta IR AG |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BEMA Buprenorphine Small moleculeMarketedNCT01298765 | Pain | Phase 3 | COMPLETED | 302 | Aug 1, 2012 | ||||||
| Buprenorphine Small moleculeMarketedNCT01871285 | Pain | Phase 3 | COMPLETED | 373 | Jul 1, 2014 | ||||||
| Buprenorphine Small moleculeMarketedNCT01675167 | Low Back Pain | Phase 3 | COMPLETED | 1,567 | Jun 1, 2014 | ||||||
| HLD200 methylphenidate Small moleculeMarketedNCT02493777 | Attention Deficit Hyperactivity Disorder | Phase 3 | COMPLETED | 288 | Mar 1, 2016 | ||||||
| Buprenorphine Small moleculeMarketedNCT00941304 | Dental Pain | Phase 2 | COMPLETED | 153 | Nov 1, 2009 | ||||||
| Belbuca 300 µg Small moleculeMarketedNCT03996694 | Respiratory Depression | Phase 1 | COMPLETED | 19 | Oct 27, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every COLL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Xtampza ER | management of pain severe enough to require daily, around-the-clock, long-term opioid treatment | 2017-02-01 | statistically significantly lower peak 'Drug Liking' (Emax) when compared with crushed immediate-release oxycodone; Xtampza ER when taken chewed was bioequivalent to taking it intact as determined by Cmax and AUC; statistically significant lower 'Take Drug Again' (Emax) when compared with crushed immediate-release oxycodoneRead More | Collegium Announces Positive Topline Results of Human Abuse Potential Clinical Trial Evaluating the Oral Abuse of Xtampza ERRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| SANTINI GINODirector | Option | 8,700 112,483 held | $16.49 | 06/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in COLL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avidity Partners | 0.2 % (-60 %) | 3.77 M | 117.00 K | -67.63% ( -244.40 K) |
COLL Institutional Ownership Trends
COLL Short Interest
Shares sold short, counted twice a month.
16.82%
Short % of Float
of tradable shares sold short
5.4M
Shares Sold Short
-2.6% vs prior count
7.2 High
Days to Cover
trading days of normal volume to buy every short share back
749.9K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How COLL ranks across every disease it competes in
Competitive Position is a premium feature
See how COLL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCOLL News
COLL▼ -1%today
Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts
Collegium Pharmaceutical and Boston Legacy FC announced an expanded partnership to support neurodivergent children, particularly those with ADHD. The initiative includes a coaching certification program and an annual summit to foster inclusivity in sports. This collaboration aims to enhance community engagement and accessibility for families across Massachusetts.
Read more →COLLCollegium to Report Third Quarter 2026 Financial Results on November 5, 2026
Collegium Pharmaceutical, Inc. will announce its third quarter 2026 financial results on November 5, 2026, before the market opens. A live conference call and webcast will follow at 8:00 a.m. ET. The company focuses on innovative treatments for CNS and pain conditions, with a notable ADHD medication portfolio.
Read more →COLLCollegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses
Collegium Pharmaceutical announced that seven abstracts from its ADHD portfolio will be presented at the AACAP and NEI Fall Congresses this fall. The studies include Phase 4 research on AZSTARYS in pediatric populations and real-world analyses of JORNAY PM in adults. These presentations aim to enhance understanding of ADHD across different ages.
Read more →COLLCollegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life
Collegium Pharmaceutical has launched Start Talking ADHD, an online resource hub designed to assist individuals with ADHD and their families in navigating care and education. The platform offers practical guides for effective communication with healthcare providers and schools. This initiative reflects Collegium's ongoing commitment to supporting the ADHD community through education and advocacy.
Read more →COLLCollegium to Participate in Upcoming Investor Conferences
Collegium Pharmaceutical, Inc. will participate in two upcoming investor conferences: the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, and the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026. Live webcasts of these events will be available on the company's website, with replays accessible for 90 days post-event.
Read more →COLL▲ +9.5%on this news
Collegium Announces $50 Million Accelerated Share Repurchase Program
Collegium Pharmaceutical has initiated a $50 million Accelerated Share Repurchase (ASR) program as part of a broader $150 million share repurchase initiative. The company aims to leverage its strong financial position and growing ADHD portfolio to enhance shareholder value. The ASR is expected to conclude by the fourth quarter of 2026, with an initial delivery of over 1.5 million shares.
Read more →COLL▼ -18.6%on this news
Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress
Collegium Pharmaceutical reported second quarter net revenues of $199.9 million, a 6 percent increase from the prior year. The company completed its acquisition of AZSTARYS, which contributed $12.9 million in partial quarter sales. JORNAY PM revenue rose 41 percent to $46.1 million, driven by strong prescription growth. Adjusted EBITDA increased 8 percent to $113.8 million for the period.
Read more →COLLCollegium to Report Second Quarter 2026 Financial Results on August 6, 2026
Collegium Pharmaceutical, Inc. announced it will report its second quarter 2026 financial results on August 6, 2026, before market opening. A live conference call and webcast will follow at 8:00 a.m. ET. The company focuses on innovative treatments for complex CNS and pain conditions.
Read more →COLLCollegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston
Collegium Pharmaceutical announced plans to relocate its corporate headquarters to One Lincoln in Boston by Q1 2027. This move signifies the company's growth and commitment to the Massachusetts community. The new location will enhance Collegium's engagement with the healthcare and life sciences sectors, supporting its mission to improve patient lives.
Read more →COLLCollegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Collegium Pharmaceutical has announced the granting of 50,305 restricted stock units (RSUs) to 34 newly hired non-executive employees as part of its 2026 Inducement Plan. This plan was adopted to comply with Nasdaq Listing Rule 5635(c)(4) and aims to enhance employee retention through a structured vesting schedule. The RSUs will vest over a three-year period, contingent on continued employment.
Read more →COLLCollegium to Participate in 2026 Jefferies Global Healthcare Conference
Collegium Pharmaceutical, Inc. will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3, 2026. The event will be available via a live webcast on the company's website, with a replay accessible for 90 days. Collegium focuses on innovative treatments for central nervous system and pain conditions.
Read more →COLLCollegium Completes Acquisition of AZSTARYS from Corium Therapeutics
Collegium Pharmaceutical has successfully acquired AZSTARYS from Corium Therapeutics, a CNS stimulant targeted for ADHD treatment. This acquisition is expected to complement Collegium's existing ADHD portfolio and enhances its financial outlook, projecting 2026 product revenues to reach between $865 and $895 million. Additionally, the company anticipates significant operational synergies and immediate revenue accretion. Collegium aims to integrate AZSTARYS into its commercial infrastructure effectively, thereby expanding treatment options available to patients and prescribers.
Read more →COLL▲ +7.7%on this newsshared move
Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress
Collegium Pharmaceutical, Inc. reported strong financial results for Q1 2026, with net revenues of $193.5 million, a 9% year-over-year increase. The ADHD treatment JORNAY PM performed particularly well, generating $38.9 million in revenue, a 36% increase from the previous year. The company is also set to acquire AZSTARYS, which is anticipated to enhance its ADHD portfolio further. Additionally, Collegium reaffirmed its full-year guidance, highlighting a solid financial position and growth strategy.
Read more →COLLCollegium to Report First Quarter 2026 Financial Results on May 7, 2026
Collegium Pharmaceutical, Inc. announced it will report its first quarter 2026 financial results on May 7, 2026, before market opening. Following the announcement, a live conference call and webcast will be held at 8:00 a.m. ET. The company is focused on enhancing its portfolio, particularly with its ADHD treatment, JORNAY PM.
Read more →COLLCollegium to Acquire AZSTARYS from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory
Collegium Pharmaceutical announced its acquisition of AZSTARYS from Corium Therapeutics for $650 million, expected to close in Q2 2026, pending regulatory approvals. This strategic acquisition aims to strengthen Collegium's existing ADHD portfolio, with AZSTARYS projected to generate significant revenue and boast strong patent protection. CEO Vikram Karnani highlighted this move as key to accelerating growth and enhancing patient care. The deal also includes potential milestone payments of up to $135 million, further emphasizing its strategic importance.
Read more →COLL▼ -5.9%on this news
Collegium to Present New Real-World Data at PainConnect 2026
Collegium Pharmaceutical, Inc. will present two posters featuring real-world data from its pain medication portfolio at PainConnect 2026. This event, hosted by the American Academy of Pain Medicine, will take place in Salt Lake City from March 5-8, 2026. The presentations aim to provide valuable insights into pain management practices.
Read more →COLLParis Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community
Collegium Pharmaceutical and Paris Hilton have launched the 'Embrace Your Sparkle' campaign to raise awareness about ADHD. The initiative aims to challenge stereotypes and promote open dialogue about the condition. Hilton shares her personal experiences with ADHD and emphasizes the importance of individualized treatment plans, highlighting her use of JORNAY PM for symptom management.
Read more →COLLCollegium Reports Fourth Quarter and Full-Year 2025 Financial Results
Collegium Pharmaceutical reported fourth-quarter net revenues of $205.4 million, a 13 percent increase from the prior year. Full-year net revenues reached a record $780.6 million, up 24 percent year-over-year. The company ended 2025 with $386.7 million in cash, cash equivalents, and marketable securities. Collegium reaffirmed its full-year 2026 financial guidance during the earnings release.
Read more →About Collegium Pharmaceutical, Inc.
Headquarters100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA, 02072
BIOPHARMAWATCH ELITE PLUS
Trade the next COLL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime